Such metabolic changes also partially appears in the serum of non-obstructed CRC patients, which should be an important reason why the serum did not show significant differences in glycolysis and glycerol fatty acid metabolism pathways between CBO and ABO in this study. The gene discussed is ABO; the disease is colorectal carcinoma.